X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Ranbaxy: Riding on the US wave - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Apr 29, 2003

    Ranbaxy: Riding on the US wave

    Powered by a 161% growth in exports, Ranbaxy Laboratories Limited, has reported a 51% growth in consolidated net sales and nearly 94% sales growth on a standalone basis in the March quarter. The company reported a 77% growth in net profits (consolidated) and nearly 195% growth in standalone profits.

    Consolidated numbers
    (Rs m) 1QFY03 1QFY04 Change FY03
    Net sales 7,345 11,102 51.2% 37,138
    Other Operating Income 118 539 356.8% 1,379
    Total operating income 7,463 11,641 56.0% 38,517
    Other income 51 77 51.0% 245
    Operating expenses 6,302 9,018 43.1% 30,606
    Operating profit 1,161 2,623 125.9% 7,911
    Operating profit margin (%) 15.6% 22.5% 44.8% 20.5%
    Interest  198 77 -61.1% 387
    Depreciation 296 372 25.7% 951
    Profit before tax and extraordinary items 718 2,251 213.5% 6,818
    Extra-ordinary Items 818 102 -87.5% 876
    Technology Licencing Income 0 0 - 640
    Tax 558 614 10.0% 1856
    Profit after Tax/(Loss) 978 1,739 77.8% 6,478
    Minority interests 1 10 900.0% 8
    PAT after minority interests 977 1,729 77.0% 6,470
    Net profit margin (%) 13.3% 15.6%   17.4%
    No. of Shares (eoy) (m) 115.9 185.5   185.5
    Earnings per share* 21.1 37.3   34.9
    *(annualised)        
    Current P/e ratio   18.1   19.3

    Overseas markets reported strong growth largely led by the generics spurt. Non-India revenues now form 81% of the company's global sales. This region reported over 78% growth during the quarter. US has emerged as Ranbaxy's largest market (accounting for 48% of global revenues). This region has grown by a strong 120% YoY during 1QFY04. In January 2003, Bayer had launched its Cipro once-a-day product (500mg) in the US market. This seems to be the likely reason for the strong US led growth. Europe too, grew by a strong 52% YoY, now accounting for over 10% of revenues. The growth in Europe region was largely spearheaded by UK, with a growth of 56% YoY. Germany also performed well with a growth of 82% over the corresponding period, though on a relatively smaller base.

    Regional sales break-up
    (US$ m) 1QFY03 1QFY04 Change % of sales in 1QFY04
    India (Rs m) 2,353 2,202 -6.4% 19.8%
    US 51 112 120.0% 48.0%
    Europe (UK, Russia, Germany, Poland) 16 24 52.0% 10.3%

    India (i.e. the domestic market), was the only soft spot in the company's performance. The company's sales dipped by a marginal 6.4% during the March quarter, in keeping with the overall slowdown in the domestic industry. As per ORG figures released by the company, the industry witnessed a flat growth of 0.7% during the March quarter. This is much slower than the 8% industry growth witnessed in the year 2002. The company also attributed the dip in domestic sales to the uncertainty over VAT, coupled with the continuous declining trend in the anti-infective market over the past eight months. India's share in Ranbaxy's revenues which stood at 32% in March quarter last year, is currently just below 20% of revenues.

    Standalone numbers
    (Rs m) 1QFY03 1QFY04 Change FY03
    Net Sales 5,289 10,249 93.8% 27,686
    Other operating income 181 648 258.0% 1,794
    Other Income 33 56 69.7% 199
    Total expenditure 4,517 7,470 65.4% 23,082
    Operating Profit (EBDIT) 953 3,427 259.6% 6,398
    Operating Profit Margin (%) 18.0% 33.4%   23.1%
    Interest 131 6 -95.4% 208
    Depreciation 198 179 -9.6% 594
    Profit before Tax 657 3,298 402.0% 5,795
    Extraordinary items 564 49 -91.3% 1,339
    Tax 272 549 101.8% 898
    Profit after Tax/(Loss) 949 2,798 194.8% 6,236
    Net profit margin (%) 17.9% 27.3%   22.5%
    No. of Shares (eoy) (m) 115.9 185.5   185.5
    Earnings per share* 20.5 60.3   33.6
    *(annualised)        
    Current P/e ratio   11.2   20.0

    Ranbaxy, which is India's largest pharma company, has emerged as a true Indian MNC. The company now sells its products in over 70 countries, with ground operations in 25 countries and manufacturing operations in 7 countries. The company's R&D expenses have shot up from 2.3% of total operating income (consolidated) last year to 5.3% during 1QFY04. This fact stresses on the company's continued focus on the global market. During the quarter, Ranbaxy received 5 approvals, taking the cumulative number of approvals to 63 (33 approvals are still pending).

    Sales break-up
    (Rs m) 1QFY03 1QFY04 Change
    Domestic 2,353 2,202 -6.4%
    Exports 3,176 8,291 161.1%
    Less: Trade discounts 240 244 1.7%
    Net Sales (standalone) 5,289 10,249 93.8%

    At Rs 674, the stock is trading at 18.1x annualised 1QFY04 earnings (consolidated). Ranbaxy continues to reap the rewards of its strategy to set up presence across the globe. The company had clocked 148% net profit rise in FY03 too, backed by a strong 38% topline increase. Owing to the stupendous rates of growth, the company's valuations look to be on the lower side. But as we have seen in the past, Indian generic companies have had a string of volatile quarters and the performance is not a benchmark of things to come. But we are enthused by the company's strong march forward globally.

     

     

    Equitymaster requests your view! Post a comment on "Ranbaxy: Riding on the US wave". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

    Aug 21, 2017

    Most Indians who cannot find jobs, look at becoming self-employed.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

    Aug 22, 2017

    Post demonetisation, a cut in bank savings deposits rates was in the offing.

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    RANBAXY LAB SHARE PRICE


    Apr 1, 2015 (Close)

    TRACK RANBAXY LAB

    • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    MARKET STATS